Changes of Plasma Concentrations of Soluble Vascular Cell Adhesion Molecule-1 and Vascular Endothelial Growth Factor after Increased Perfusion of Lower Extremities in Humans

Endothelium ◽  
2003 ◽  
Vol 10 (3) ◽  
pp. 159-165 ◽  
Author(s):  
Caroline Schmidt-Lucke ◽  
Dirk Reinhold ◽  
Siegfried Ansorge ◽  
Helmut Klein ◽  
J. André Schmidt-Lucke
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Cell Adhesion ◽  
Growth Factor ◽  
Cell Adhesion Molecule ◽  
Plasma Concentrations ◽  
Vascular Endothelial ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Cell Adhesion Molecule 1 ◽  
Endothelial Growth Factor

scholarly journals Recombinant vascular endothelial growth factor 121 decreases vascular cell adhesion molecule-1 in murine pre-eclampsia model placenta

2016 ◽  
Vol 35 (3) ◽  
pp. 192
Author(s):  
Sri Sulistyowati ◽  
John Arianto Sondakh ◽  
Eric Edwin Yuliantara ◽  
Supriyadi Hari Respati ◽  
Soetrisno Soetrisno
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Adhesion Molecule ◽  
Angiogenic Factor ◽  
Vascular Endothelial ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Pregnant Mice ◽  
Cell Adhesion Molecule 1 ◽  
Endothelial Growth Factor

Background<br />Preeclampsia is one of the major contributors to maternal and fetal morbidity and mortality. Imbalance of soluble Fms-like tyrosine kinase (sFlt-1) as anti-angiogenic factor and vascular endothelial growth factor (VEGF) as pro-angiogenic factor plays a role in the pathogenesis of preeclampsia. Endothelial dysfunction in preeclampsia causes vascular cell adhesion molecule-1 (VCAM-1) to be expressed on its surface. This study aims to evaluate the effect of recombinant VEGF-121 on VCAM-1 expression in the placenta of a murine preeclampsia model. <br /><br />Methods <br />An experimental analytical study conducted from February until March 2016 in the Biomedical Laboratory, Faculty of Veterinary Medicine, Airlangga University. The study sample consisted of 30 pregnant mice, divided into three groups, i.e. 10 normal pregnant mice, 10 mice with preeclampsia model and 10 mice with preeclampsia model and recombinant VEGF-121 therapy. All animals were subjected to immunohistochemical examination of VCAM-1 expression in their placentas. The results were assessed semiquantitatively according to a modified Remmele method. Data analysis was done using one-way ANOVA and Tukey’s multiple comparisons method. <br /><br />Results<br />Mean VCAM-1 expression in normal (0.97 ± 0.54%) murine placentas, compared with placentas (2.94 ± 0.96%) of murine preeclampsia models (p=0.000), while mean VCAM-1 expression in placentas of murine preeclampsia models with VEGF intervention was 2.14 ± 0.68% (p=0.030).<br /><br />Conclusion <br />Recombinant VEGF-121 can reduce VCAM-1 expression in placentas of murine preeclampsia models. The present study has shown the potential benefits of VEGF therapy, justifying serious consideration of this therapeutic approach for use in women with preeclampsia.

Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy

2004 ◽  
Vol 22 (9) ◽  
pp. 1655-1663 ◽  
Author(s):  
Shahrokh F. Shariat ◽  
Veronica A. Anwuri ◽  
Dolores J. Lamb ◽  
Nina V. Shah ◽  
Thomas M. Wheeler ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Cell Adhesion Molecule ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Localized Disease ◽  
Biochemical Progression ◽  
Cell Adhesion Molecule 1 ◽  
Endothelial Growth Factor

Purpose Angiogenesis is a critical process for cancer progression. We tested whether elevated circulating levels of the angiogenesis-related markers vascular endothelial growth factor (VEGF) and/or soluble vascular cell adhesion molecule-1 (sVCAM-1) are associated with prostate cancer diagnosis, stage, progression, and metastasis. Patients and Methods Plasma levels of VEGF and sVCAM-1 were measured on frozen, archival plasma obtained preoperatively from 215 consecutive patients who underwent radical prostatectomy for clinically localized disease, nine men with untreated prostate cancer metastatic to bones, and 40 healthy men without cancer. Results Plasma levels of both VEGF and sVCAM-1 were highest in patients with bone metastases (P < .001). VEGF levels were higher in patients with clinically localized disease than in healthy controls (P < .001). VEGF levels were elevated in patients with biopsy and final Gleason sum ≥ 7 (P = .036 and P = .020, respectively) and extraprostatic extension (P = .047). Higher preoperative VEGF was independently associated with metastases to lymph nodes (P < .001). Both VEGF and sVCAM-1 were independently associated with biochemical progression after adjustment for the effects of standard preoperative features (P = .014 and P = .039, respectively). VEGF remained independently associated with biochemical progression after adjustment for standard postoperative features (P = .019). Conclusion Plasma levels of VEGF increased incrementally from healthy controls to patients with clinically localized disease to patients with lymph node and skeletal metastases. Higher preoperative VEGF was independently associated with metastases to lymph nodes and biochemical progression after surgery in both pre- and postoperative models. Plasma sVCAM-1 was elevated in men with bone metastases and was associated with biochemical progression in a preoperative model.

Sign in / Sign up

Export Citation Format

Share Document